MoneyWeek’s comprehensive guide to this week’s share tips
Apr 08, 2022
3 minutes
Three to buy
ConvaTec
Shares
he transformation of this medical-technology firm “appears to be bearing fruit”. The group registered 7.9% growth from its top 12 priority markets in 2021, and expects to deliver organic sales growth of between 4% and 5.5% for 2022. Focused acquisitions are helping growth, non-core businesses have been sold and efficiency measures have paid off. It’s the “clear market leader” in the disposable infusion market: its infusion sets, used by diabetic patients,.
You’re reading a preview, subscribe to read more.
Start your free 30 days